What is RareCyte?
Established in 2009, RareCyte specializes in the development of sophisticated technologies designed for the analysis of rare single cells in blood. By providing researchers and clinicians with high-precision tools, the company facilitates deeper insights into complex biological processes, which is critical for advancements in oncology, immunology, and personalized medicine. RareCyte operates at the intersection of hardware and software innovation, ensuring that laboratories can achieve accurate, reproducible results in the detection and characterization of rare cell populations. Its market position is defined by a robust intellectual property portfolio and a clear focus on enhancing diagnostic accuracy through advanced instrumentation.
How much funding has RareCyte raised?
RareCyte has raised a total of $97M across 5 funding rounds:
Private Equity
$30M
Unspecified
$22M
Debt
$1M
Unspecified
$24M
Other Financing Round
$20M
Private Equity (2017): $30M with participation from 5AM Ventures and Telegraph Hill Partners
Unspecified (2019): $22M led by HealthQuest Capital, Ron Seubert, and 5AM Ventures
Debt (2020): $1M supported by PPP
Unspecified (2021): $24M featuring F-Prime Capital Partners, 5AM Ventures, Agilent, HealthQuest Capital, Arboretum Ventures, and Logos Capital
Other Financing Round (2024): $20M backed by Agilent, Arboretum Ventures, The Forest Road, F-Prime Capital Partners, 5AM Ventures, and HealthQuest Capital
Key Investors in RareCyte
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Agilent
Agilent Technologies is a global leader in life sciences, diagnostics, and applied markets, providing laboratories worldwide with advanced instruments, software, consumables, and services.
Arboretum Ventures
Arboretum Ventures is a Midwest-based healthcare venture capital firm with over 20 years of experience in investing in innovative healthcare solutions, focusing on early-stage startups to improve patient outcomes.
What's next for RareCyte?
With the recent influx of capital, RareCyte is well-positioned to accelerate its research and development initiatives, particularly in the refinement of its single-cell analysis platforms. The company is expected to leverage this strategic backing to enhance its commercial reach, potentially entering new international markets and broadening its diagnostic applications. As the life sciences industry continues to prioritize precision medicine, RareCyte's ability to integrate its technology into clinical workflows will be a primary driver of its future growth. The firm remains focused on scaling its operations to meet the increasing demand for high-fidelity cellular data, ensuring it remains a key player in the evolution of modern diagnostics.
See full RareCyte company page
